JPS6327425A - Remedy for acne vulgaris - Google Patents
Remedy for acne vulgarisInfo
- Publication number
- JPS6327425A JPS6327425A JP61171354A JP17135486A JPS6327425A JP S6327425 A JPS6327425 A JP S6327425A JP 61171354 A JP61171354 A JP 61171354A JP 17135486 A JP17135486 A JP 17135486A JP S6327425 A JPS6327425 A JP S6327425A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- remedy
- acne vulgaris
- ingredient
- bisabolol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 18
- 206010000496 acne Diseases 0.000 title claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 11
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 11
- 229940036350 bisabolol Drugs 0.000 claims abstract description 11
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 11
- 239000000341 volatile oil Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 239000004615 ingredient Substances 0.000 abstract description 7
- 238000002156 mixing Methods 0.000 abstract description 5
- 229920001296 polysiloxane Polymers 0.000 abstract description 3
- 125000004122 cyclic group Chemical group 0.000 abstract description 2
- 240000004752 Laburnum anagyroides Species 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 9
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- -1 jojoba oil Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000008163 avocado oil Substances 0.000 description 4
- 235000021302 avocado oil Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- LOIMOHMWAXGSLR-UHFFFAOYSA-N 2-hexyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCC LOIMOHMWAXGSLR-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241000577986 Myoporum Species 0.000 description 1
- 241001358150 Myrocarpus Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- GQXQIRNPJBUEGY-UHFFFAOYSA-N hexadecan-7-yl 2,2-dimethyloctanoate Chemical compound CCCCCCCCCC(CCCCCC)OC(=O)C(C)(C)CCCCCC GQXQIRNPJBUEGY-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 239000004306 orthophenyl phenol Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- SVETUDAIEHYIKZ-IUPFWZBJSA-N tris[(z)-octadec-9-enyl] phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOP(=O)(OCCCCCCCC\C=C/CCCCCCCC)OCCCCCCCC\C=C/CCCCCCCC SVETUDAIEHYIKZ-IUPFWZBJSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は尋常性五迩治療薬に関し、更に詳しくは、過剰
分泌している皮脂に速やかに浸透して皮脂tS解するの
で綿などで清拭することによりこれを効率工〈除去する
ことができると共に、患部やその周辺の皮膚に刺激を与
えることなく原因菌を殺滅し、しかもその効果が持続す
る尋常性座癒治療薬に関する。[Detailed Description of the Invention] [Field of Industrial Application] The present invention relates to a drug for treating vulgaris, and more specifically, it quickly penetrates into excessively secreted sebum and dissolves sebum tS, so it can be cleaned with cotton or the like. To provide a therapeutic agent for acne vulgaris that can be efficiently removed by wiping, kills causative bacteria without irritating the affected area or the surrounding skin, and has a lasting effect.
従来より、尋常性、4@(いわゆる「にきび」)の最も
基本的な治療法は洗浄による脱脂と殺菌であるとされて
きた。にきびは一般に皮脂分泌の多い思春期に発生する
もので、面庖形成と脂腺の細菌感染が誘因でらる。感染
原因となる細菌は、ブドウ状球菌が主で、その他Am桿
菌、白色球菌。Conventionally, the most basic treatment for acne vulgaris, 4@ (so-called "acne") has been considered to be degreasing and sterilization through washing. Acne generally occurs during adolescence, when sebum production is high, and is caused by acne formation and bacterial infection of the sebaceous glands. The bacteria that cause infection are mainly Staphylococcus, and others include Am bacillus and White coccus.
ビールスなどもめげられる。従って1石鹸などで頻繁に
洗浄することにLって過剰分泌している皮脂を除去し、
その後、殺菌剤やサルファ剤配合の薬剤を塗布すること
によって、原因菌を殺菌するのが最も一般的な治療法で
6った。Beerus and others are also defeated. Therefore, frequent washing with soap etc. will remove excess sebum,
The most common treatment is then to kill the causative bacteria by applying a fungicide or a drug containing sulfa drugs6.
にきびの発生する時期は、主として10代半ばから20
代半ばである。この時期は、−日のほとんどを学校ある
いは職場ですごすことが多く、励行されるべき洗顔t−
頻繁に行なうことが困難でろるのが実状でめる。そして
、そのまま薬物を塗布すれば、このことが、かえって脂
腺をつまらせて、感染部位を増悪することになるのであ
る。嘔らK。Acne mainly occurs from mid-teens to late 20s.
He is in his mid-teens. During this period, most of the day is spent at school or work, and facial washing is a must.
The reality is that it is difficult and frustrating to do it frequently. If the drug is applied as is, this will actually clog the sebaceous glands and worsen the infection. Yora K.
この時期は、自分の容貌に対して非常に感受性が高いの
で、止むを得ず日に何度も薬剤だけを塗っ友り1手で頻
繁に触ったりして、自ら患部を悪化させていることが多
い。At this stage, they are extremely sensitive to their own appearance, so they have no choice but to apply medicine multiple times a day, touch their skin frequently with one hand, and end up making the affected area worse themselves. There are many.
一方、従来、にきび治療薬には、一般に、イオウ、力/
フル、アルコール等を配合した脱脂、殺菌を目的とする
液剤、及びサルファ剤、殺菌剤。On the other hand, conventional acne treatment drugs generally contain sulfur,
Liquid agents for the purpose of degreasing and sterilization that contain alcohol, sulfa drugs, and disinfectants.
抗炎症剤を配合し次殺菌、抗炎症を目的とする軟膏又は
クリームがある。しかし、これらの治療剤は、もっばら
、にきびの原因を除去することのみに向けられており、
皮膚組成に対する影響は殆んど考慮されていない。従っ
て、当該治療剤を何回も塗布すると、炎症を起している
丘疹の周囲にある皮膚が必要以上に脱脂されたり、正常
な生理機能がそこなわれ次すすることがめる。There are ointments and creams that contain anti-inflammatory agents and have antibacterial and anti-inflammatory purposes. However, these treatments are solely aimed at eliminating the cause of acne;
Effects on skin composition are rarely considered. Therefore, if the therapeutic agent is applied many times, the skin surrounding the inflamed papules may be unnecessarily degreased and normal physiological functions may be impaired.
従って、手軽にどこでも簡単に皮膚を脱脂および清潔に
することができ、しかも患部およびその周辺の皮膚に刺
激を与えず、生理機能を保持し。Therefore, it is possible to easily degrease and cleanse the skin anywhere, while maintaining physiological functions without irritating the affected area and the surrounding skin.
有効な殺菌効果を示す低刺激性の尋常性^癒治療薬がの
ぞまれていた。There was a need for a hypoallergenic medicine for the treatment of vulgaris that has an effective bactericidal effect.
斯かる実情において1本発明者は鋭意研究を行った結果
、特定組成の油性基剤にビサボロールを配合したものが
上記目的を満足することを見出し。Under these circumstances, the present inventor conducted extensive research and found that a mixture of bisabolol in an oily base having a specific composition satisfies the above objectives.
本発明を完成した。The invention has been completed.
すなわち1本発明は1次の成分ta)〜(dl(&)ビ
サポa−ル。That is, the present invention consists of primary components ta) to (dl(&) bisapol.
(b)油状物質。(b) Oily substances.
(C)揮発油、 (d)低級アルコール。(C) volatile oil, (d) Lower alcohol.
を含有することを特徴とする尋常性&街治療剤を提供す
るものでるる。This product provides a therapeutic agent for common and common diseases characterized by containing.
本発明のta+成分であるビサボロールはそれ自体を用
いてもよいが、ビサボロール含有植物抽出エキスとして
配合式れてもよい。ビサボロール含有II物抽出エキス
は、カミツレ、ポプラ、ミロカルブx (Myroca
rpus frorndosus ) 、エフアール魯
アレム(Fr、Allem ) 、ラベンダー(L、o
fficinalisChaix ) 、バーrヂンチ
ョウ(Myoporum CrcssifoliumF
orst )等の植物からエタノール、エーテル、アセ
トン等の有機溶媒で抽出することにより得られる。(a
l成分は、ビサボロール又はこれを含む植物エキスは全
組成の0.025〜lO重量%(以下、単にシで示す)
が好ましい。Bisabolol, which is the ta+ component of the present invention, may be used as such, but it may also be blended as a bisabolol-containing plant extract. Bisabolol-containing compound II extract contains chamomile, poplar, Myrocarb
rpus frondosus), Fr, Allem, lavender (L, o
fficinalisChaix), Bird's-headed butterfly (Myoporum Crcsifolium F.
orst) by extraction with an organic solvent such as ethanol, ether, or acetone. (a
Ingredient 1 is bisabolol or a plant extract containing it, which is 0.025 to 10% by weight of the total composition (hereinafter simply indicated by ``shi'')
is preferred.
(bl成分の油状物質としては、アボカド油、アルモン
ド油、オリーブ油、水添オリーブ油、力aット油、キュ
ーカ/バー油、キヨウニン油、サザ/カ油、ツバキ油、
ヒマワリ油、サフラワー油、ホホバ油、ゴマ油、パーム
油、綿実油、ヤシ油等の植物油;ラノリン、タードル油
、ミツロウ、ミ/り油、スクワレノ、スクワラ/、プリ
スタン等の動物油;グリセリントリー2−エチルヘキサ
ノエート等のトリダリセライド、ラウリ/酸、ミリスチ
ン酸、パルミチン酸、ステアリン酸、インステアリン酸
、オレイ/酸、リノール酸、リシノール酸、ベヘ二)酸
、ラノリン脂肪酸などの脂肪酸。(The oily substances of the BL component include avocado oil, almond oil, olive oil, hydrogenated olive oil, acacia oil, cuca/bar oil, quince oil, soybean oil, soybean oil, camellia oil,
Vegetable oils such as sunflower oil, safflower oil, jojoba oil, sesame oil, palm oil, cottonseed oil, coconut oil; Animal oils such as lanolin, tardle oil, beeswax, millet oil, squaleno, squala/, pristane; glycerin-tri-2-ethyl Tridaliserides such as hexanoate, fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, instearic acid, oleic acid, linoleic acid, ricinoleic acid, behenic acid, lanolin fatty acid.
ラウリルアルコール、セタノール、2−へキシルドデカ
ノール、ステアリルアルコール、インステアリルアルコ
ール、オレイルアルコール、2−オクチルドデカノール
、ベヘニルアルコール、ラノリンアルコール、コレステ
ロール、フィトステロール等f)18級アルコール、エ
チレングリコール。Lauryl alcohol, cetanol, 2-hexyldodecanol, stearyl alcohol, instearyl alcohol, oleyl alcohol, 2-octyldodecanol, behenyl alcohol, lanolin alcohol, cholesterol, phytosterol, etc. f) 18th alcohol, ethylene glycol.
エチレ7グ’)コールモノアルキルエーテル、ジエチレ
/グリコールモノエチルエーテル、トリエチレ/クリコ
ール、ポリエチレングリコール、プロピレングリコール
、ポリフロピレンゲリコール。Ethylene 7g')col monoalkyl ether, diethyl/glycol monoethyl ether, triethylene/glycol, polyethylene glycol, propylene glycol, polypropylene gellicol.
1.3−ブチレノグリコール、グリセリン、ポリクリセ
リン、バチルアルコール、ペンタエリスリトール等の多
価アルコール類、アジビン酸ジイソプロピル、インステ
アリン酸へキシルデシル、イソオクタノ酸セチル、オレ
イン酸オレイル、オレイン酸デシル、酢酸ラノリ/、ジ
メチルオクタン酸へキシルデシル、ステアリン酸ブチル
、セバシン酸ジイソプロピル、トリオレイルリン酸、乳
酸セチル、乳酸ミリスチル、パルミチン酸インブロピル
、ミリスチン酸イソブaビル、フタル酸ジエチル、ミリ
スチン酸オクチルドデシル、ミリスチン酸ミリスチル、
ラウリン酸ヘキシルなどのエステル類、流動ポリイソブ
チレン、α−オレフイ/オリゴマー、スクワラ/、セレ
シン等の炭化水素類などの合成油が皺げられる。これら
の油状物質は、揮発油による過剰な皮脂の除去を防止し
、皮膚に適度な油性を与える九めのものであり、その配
合量は2〜50%、特に5〜30%が好ましい。1.3-Butylenoglycol, glycerin, polycrycerin, batyl alcohol, polyhydric alcohols such as pentaerythritol, diisopropyl adibate, hexyldecyl instearate, cetyl isooctanoate, oleyl oleate, decyl oleate, lanoli acetate/ , hexyldecyl dimethyloctanoate, butyl stearate, diisopropyl sebacate, trioleyl phosphate, cetyl lactate, myristyl lactate, imbropyl palmitate, isobuavir myristate, diethyl phthalate, octyldodecyl myristate, myristyl myristate,
Synthetic oils such as esters such as hexyl laurate, fluid polyisobutylene, α-olefins/oligomers, squara/hydrocarbons such as ceresin, etc. are wrinkled. These oily substances prevent the removal of excess sebum by volatile oils and impart appropriate oiliness to the skin, and their blending amount is preferably 2 to 50%, particularly 5 to 30%.
(c)成分の揮発油としては1例えば鎖状又は環状ンリ
コー/、R,動イソパラフイ7等で5℃における粘度が
toes 以下のものが皐げられる。揮発油は皮脂を
除去する作用を奏するものであり、その配合量は10〜
70%、特に20〜60%が好ましい。これより少ない
と皮脂の除去が不充分となり、ま次長すぎると皮脂の除
去が過多となり好ましくない。As the volatile oil for component (c), there may be used, for example, chain or cyclic NRICOH/R, dynamic isoparaphyte 7, etc., which has a viscosity at 5 DEG C. or less. Volatile oil has the effect of removing sebum, and its blending amount is 10~
70%, especially 20-60% is preferred. If the length is less than this, the removal of sebum will be insufficient, and if the length is too long, too much sebum will be removed, which is undesirable.
(dl成分の低級アルコールとしては、例えばエタノー
ル、イソプロパノール等が使用される。この低級アルコ
ールは、(b)成分の油状物質と(cl成分の揮発油の
相溶性を工くするために配合されるもので、その配合量
は10〜80%、特に10〜605が好ましい。(As the lower alcohol for the dl component, ethanol, isopropanol, etc. are used, for example. This lower alcohol is blended to improve the compatibility between the oily substance of the (b) component and the volatile oil of the (cl) component. The blending amount is preferably 10 to 80%, particularly 10 to 60%.
上記必須成分(al〜(dlに更にfa)以外の抗菌性
物質を配合すると、更に有効な治療効果が得られる。When antibacterial substances other than the above-mentioned essential components (al to (dl and further fa)) are blended, a more effective therapeutic effect can be obtained.
当該抗菌性物質としては、例えばタロルキシレノール、
塩化べ/ゼトニウム、インプロピルメチルフェノール、
チモール、レゾルシン、塩化リソチー A 、 り/I
/:! 7酸/ロルヘキシジン、オルトフェニルフェノ
ール、ソルビン酸、デヒドロ酢酸1次亜塩素酸ナトリウ
ム、ヨウ素、ヨードチンキ、ポビドンヨード、ホウ酸、
ホウ砂、オキジドール。Examples of the antibacterial substance include talolxylenol,
Be/zethonium chloride, inpropylmethylphenol,
Thymol, resorcinol, lysothychloride A, Ri/I
/:! 7-acid/lorhexidine, orthophenylphenol, sorbic acid, dehydroacetic acid primary sodium hypochlorite, iodine, iodine tincture, povidone-iodine, boric acid,
Borax, Oxidor.
過マンガン酸カリウム、ホルマリ/、フェノール。Potassium permanganate, formali/, phenol.
ヘキサクローフェン、クレオンート、塩化メチルロサリ
ニノ、塩化ベンザルコニウム、ラウリル硫酸ナトリウム
、尿素、塩化アルキルポリアミノエチルグリシン、イク
タモール等が挙げられる。これらの抗菌性物質は、斯か
る場合に単独で配合される標準配合量のl/l O〜l
/2000で充分な効果が得られる。Examples include hexaclofen, creonate, methylrosalinino chloride, benzalkonium chloride, sodium lauryl sulfate, urea, alkyl polyaminoethylglycine chloride, ictamol, and the like. These antibacterial substances should be added at a standard blending amount of 1/1 O to 1 when used alone in such cases.
A sufficient effect can be obtained at /2000.
を九1本発明の尋常性左街治療薬には、必要に応じて、
他の消炎剤、ビタミン剤、抗酸化剤、湿潤剤、収れん剤
、抗ヒスタミン剤、抗生物質、サルファ剤、香料1着色
料等を配合することもできる。91. The drug for treating Zuigai vulgaris of the present invention may optionally include:
Other anti-inflammatory agents, vitamins, antioxidants, humectants, astringents, antihistamines, antibiotics, sulfa drugs, fragrances, colorants, etc. can also be blended.
本発明治療薬は、粘度が30cs 以下(5℃)になる
ように調製すると皮脂の除去がさらに容易になると共に
、べとつきが少なくなるのでより好ましい。It is more preferable for the therapeutic agent of the present invention to be prepared to have a viscosity of 30 cs or less (at 5° C.), since this makes it easier to remove sebum and reduces stickiness.
この治療薬はスプレーあるいはスクイズボトル等に充填
して携帯に便利な形態とするのが好ましい0
〔作用及び効果〕
本発明の尋常性ル煩治療薬は次の作用及び効果を有する
。This therapeutic agent is preferably filled into a spray or squeeze bottle to make it convenient to carry. [Actions and Effects] The therapeutic agent for common vulgaris of the present invention has the following actions and effects.
■ 低粘性の油性基剤は、皮膚に過剰分泌している皮月
旨を工〈溶解するので、皮膚面を綿等で清拭するだけで
簡単に皮脂を除去できる。■ The low-viscosity oil base works by dissolving excess sebum secreted on the skin, so sebum can be easily removed by wiping the skin surface with cotton.
■ 低粘性の油性基剤は、清拭綿等と皮膚面との機械的
摩擦を低減するので皮膚をいためない。■ The low-viscosity oily base reduces mechanical friction between the cotton and the skin surface, so it does not damage the skin.
■ 揮発性の主基剤〔(C)成分〕及び低級アルコール
は塗布後揮発して残存しないので、皮膚面においで薬物
濃度が高まって効果が増大する。(2) Since the volatile main base [component (C)] and lower alcohol evaporate and do not remain after application, the drug concentration increases on the skin surface and the effect increases.
■ 残存成分は薄い油性皮膜でおおわれるので。■ The remaining ingredients are covered with a thin oily film.
効果が持続する。The effect lasts.
■ ビサボロールの抗菌、抗炎症及び抗潰瘍作用によっ
て、にきびが有効に治療される。■ Bisabolol's antibacterial, anti-inflammatory and anti-ulcer properties effectively treat acne.
次に実施例ヲ楯げて説明する。 Next, an example will be explained.
実施例1
(1)本発明品lの調製
■油溶性カミツレエキス 5g(ビサボロール
約5ダ/、!9 )
■クロルキシレノール 0.00551■トーレ
シリコーン 5H34450,9(3JR状シリコーン
オイル)
■出光IPソルベント toy(流動インパ
ラフィン)
■アボカド油 59■エタノール
残(全100.9)室温で、■、■及び■
を混合し、これに攪拌下■及び■を加え、2時間攪拌し
た後、■を加え粘度3cs(5℃)のにきび治療薬を得
之。Example 1 (1) Preparation of product 1 of the present invention ■Oil-soluble chamomile extract 5g (bisabolol approx. 5 da/,!9) ■Chlorxylenol 0.00551 ■Toray Silicone 5H34450,9 (3JR silicone oil) ■Idemitsu IP Solvent toy (liquid imparaffin) ■Avocado oil 59■Ethanol remainder (total 100.9) At room temperature, ■, ■, and ■
2 and 3 were added to the mixture while stirring, and after stirring for 2 hours, 2 was added to obtain an acne treatment with a viscosity of 3 cs (5°C).
(11)本発明品lの使用試験 尋常性戊癒の患者9名に本発明品し?使用させ。(11) Use test of the invention product I Has this invention been applied to 9 patients with vulgaris? Let me use it.
その効果(にきびに治療効果)?調べ友。Its effect (therapeutic effect on acne)? Research friend.
結果:非常に効果あり 3名
効果ろり 4名
や\効果あり 2名
(冊 比較品1との対比試験
()1)と同じ患者9名に使用させ、その使用効果(顔
のかさかさ感及び治療効果)ヲ調べ念。Results: Very effective (3 people) Effective, 4 people (Effective), 2 people (Effective) Effect) wo investigation mind.
比較品l :イオウ・カンフルロ−ジョンイオウ
609
カンフル 5g
アラビアゴム末 30g
水酸化カルシウム 1g
芳香剤 適 量
水 残(100g)結果二本発明品
lが非常によい 2名
本発明品1がよい 5名
同等である 2名
比較11HJ 1
(1) 比較品2の調製
■りaルキシレノール o、otg■トーレシリコ
ーン 5H34450fi■出光IPソルベント
15.9■アボカド油 5I■
エタノール 残(10(1)室温で、■、■
及び■を混合し、これに攪拌下■を加え、2時間攪拌し
た後、■を加えにきび治療薬を得た。Comparison product L: Sulfur/camphorulose sulfur
609 Camphor 5g Gum arabic powder 30g Calcium hydroxide 1g Air freshener Appropriate amount Water Remaining (100g) Results 2 Invention product 1 is very good 2 people Invention product 1 is good 5 people are the same 2 people comparison 11HJ 1 (1 ) Preparation of comparative product 2■Raxylenol o,otg■Toray silicone 5H34450fi■Idemitsu IP solvent
15.9■Avocado oil 5I■
Ethanol residue (10(1) at room temperature,■,■
and (2) were mixed, and (2) was added thereto under stirring. After stirring for 2 hours, (2) was added to obtain an acne treatment.
(11) 比較品2の刺激性試験
実施例1の(11)と同様にして、比較品2の刺激性(
かゆみ、ヒリヒリ感〕全調べ文。(11) Irritation test of comparative product 2 In the same manner as (11) of Example 1, the irritation (
Itching, tingling] Complete investigation.
結果:感じる 5名
特に感じない 4名
(Ill) 本発明品lとの対比試験実施例1のam
と同様にして試験した。Results: 5 people felt it, 4 people didn't feel it (Ill) Am of Example 1 of comparative test with the invention product 1
Tested in the same manner.
結果二本発明品lが非常によい 81名・本発明品lが
よい 1名
比較例2
(1) 比較品3の調製
ビサボロール0.3,9. アボカド油50g、エタノ
ール49.79に室温で2時間攪拌して調製した。Result 2: Invention product 1 is very good 81 people ・Invention product 1 is good 1 person Comparative example 2 (1) Preparation of comparative product 3 Bisabolol 0.3, 9. It was prepared by stirring 50 g of avocado oil and 49.79 g of ethanol at room temperature for 2 hours.
(11)比較品3の使用感試験
実施例1の(11)と同様にして、使用感(べとつき)
全調べ念。(11) Feeling of use test for comparison product 3 Test of feeling of use (stickiness) in the same manner as in (11) of Example 1.
I've researched everything.
結果:感じる 8名
特に感じない 1名
(ill) 本発明品1との対比試験実施例1の(1
1Dと同様にして試験した。Results: 8 people felt it. 1 person didn't feel it.
Tested in the same manner as 1D.
結果二本発明品1が非常によい 9名
以上
手続補正書(自発)
昭和61年 8月21日
昭和61年特許願第 171354 号2、 発明の
名称
尋常性覆癒治療薬
3、 補正をする者
事件との関係 出願人
名 称 (091)花王株式会社
、61.8.二2
6、補正の対象
明細書の「発明の詳細な説明」の欄
7、 補正の内容
(1] 明細書中、第5頁第1〜3行[ミロカルブス
(Myroearpum frorndosum )
。Result 2 Invented product 1 is very good Procedural amendment written by 9 or more people (voluntary) August 21, 1988 Patent application No. 171354 of 1988 2 Title of invention vulgaris treatment drug 3 Make amendment Relationship to the case filed by the applicant Applicant name (091) Kao Corporation, 61.8. 22 6. Column 7 of "Detailed Description of the Invention" of the specification subject to amendment, Contents of amendment (1) In the specification, page 5, lines 1 to 3 [Myroearpum frondosum]
.
エフアール・アレム(Fr、人Item ) Jとある
を
[ミロカルブス(Myrocarpus fromdo
sus ′Fr Allam) Jと訂正する。Fr Alemu (Fr, Person Item) J and Aruo [Myrocarpus fromdo]
sus 'Fr Allam) J.
Claims (1)
0重量%、(c)成分10〜70重量%及び(d)成分
10〜80重量%を含有するものである特許請求の範囲
第1項記載の尋常性■瘡治療薬。 3、5℃における粘度が30cs以下である特許請求の
範囲第1項記載の尋常性■瘡治療薬。[Claims] 1. It is characterized by containing the following components (a) to (d): (a) bisabolol, (b) oily substance, (c) volatile oil, and (d) lower alcohol. Treatment for acne vulgaris. 2, (a) component 0.3 to 10% by weight, (b) component 2 to 5
The acne vulgaris therapeutic drug according to claim 1, which contains 0% by weight, 10 to 70% by weight of component (c), and 10 to 80% by weight of component (d). The acne vulgaris therapeutic agent according to claim 1, which has a viscosity of 30 cs or less at 3.5°C.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61171354A JPH0755900B2 (en) | 1986-07-21 | 1986-07-21 | Acne vulgaris remedy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61171354A JPH0755900B2 (en) | 1986-07-21 | 1986-07-21 | Acne vulgaris remedy |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6327425A true JPS6327425A (en) | 1988-02-05 |
JPH0755900B2 JPH0755900B2 (en) | 1995-06-14 |
Family
ID=15921635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61171354A Expired - Fee Related JPH0755900B2 (en) | 1986-07-21 | 1986-07-21 | Acne vulgaris remedy |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0755900B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380763A (en) * | 1992-11-19 | 1995-01-10 | Takasago International Corporation | Topical composition for treating acne vulgaris |
JP2005232173A (en) * | 2004-02-18 | 2005-09-02 | Merck Patent Gmbh | Topical composition containing at least one kind of aryl oxime and bisabolol |
FR2922765A1 (en) * | 2007-10-25 | 2009-05-01 | Inst Rech Pour Le Dev I R D Et | Use of essential oil or its fraction from Scrophulariales, e.g. for preparing a cosmetic or pharmaceutical composition to prevent and treat skin disorders and consequences of e.g. suntan, burns, acne, psoriasis and eczema |
CN108619020A (en) * | 2018-06-13 | 2018-10-09 | 广州喜澳化妆品有限公司 | A kind of facial mask and preparation method thereof containing Myoporum bontiodes extract |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59219227A (en) * | 1983-04-06 | 1984-12-10 | ロリアル | Acne treating composition |
-
1986
- 1986-07-21 JP JP61171354A patent/JPH0755900B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59219227A (en) * | 1983-04-06 | 1984-12-10 | ロリアル | Acne treating composition |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380763A (en) * | 1992-11-19 | 1995-01-10 | Takasago International Corporation | Topical composition for treating acne vulgaris |
JP2005232173A (en) * | 2004-02-18 | 2005-09-02 | Merck Patent Gmbh | Topical composition containing at least one kind of aryl oxime and bisabolol |
FR2922765A1 (en) * | 2007-10-25 | 2009-05-01 | Inst Rech Pour Le Dev I R D Et | Use of essential oil or its fraction from Scrophulariales, e.g. for preparing a cosmetic or pharmaceutical composition to prevent and treat skin disorders and consequences of e.g. suntan, burns, acne, psoriasis and eczema |
WO2009090345A2 (en) * | 2007-10-25 | 2009-07-23 | Institut De Recherche Pour Le Developpement I.R.D. | Use of essential oil for preparing a cosmetic or pharmaceutical composition |
WO2009090345A3 (en) * | 2007-10-25 | 2009-11-26 | Institut De Recherche Pour Le Developpement I.R.D. | Use of essential oil for preparing a cosmetic or pharmaceutical composition |
CN108619020A (en) * | 2018-06-13 | 2018-10-09 | 广州喜澳化妆品有限公司 | A kind of facial mask and preparation method thereof containing Myoporum bontiodes extract |
CN108619020B (en) * | 2018-06-13 | 2022-02-01 | 广州喜澳化妆品有限公司 | A facial mask containing herba Ixeritis Sonchifoliae extract and its preparation method |
Also Published As
Publication number | Publication date |
---|---|
JPH0755900B2 (en) | 1995-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3006572B2 (en) | Skin preparation | |
EP2566488B1 (en) | Povidone-iodine topical composition | |
JP4010574B2 (en) | Topical skin preparation | |
CA2685321C (en) | Solubilized delivery system for topical anesthetics | |
WO2013018884A1 (en) | Keratotic plug regrowth inhibition agent, keratotic plug regrowth inhibition method, and keratotic plug regrowth inhibition kit | |
US20070092475A1 (en) | Methods for enhancing the morphology, tone, texture and/or appearance of skin using a Meadowestolide | |
US20110236503A1 (en) | Topical Skincare Composition | |
US12029757B2 (en) | Lipid barrier repair | |
JPS6327425A (en) | Remedy for acne vulgaris | |
US7128933B2 (en) | Composition and method for the treatment of personal odors | |
US8507007B2 (en) | Dermatological composition that can be used in particular for the care and prevention of eschars | |
Lamb | Sodium bicarbonate: an excellent deodorant | |
JPS6333326A (en) | Antibacterial composition | |
US20110045096A1 (en) | Solubilized delivery system for topical anesthetics | |
JPH05186328A (en) | Skin washing and cleanly wiping agent composition | |
KR102038366B1 (en) | Cosmetic composition for improving acne skin | |
JP2022051525A (en) | External composition | |
JP4104720B2 (en) | Ultrasonic diagnostic coating composition | |
JPS58103319A (en) | Composition for skin application | |
JPS6322506A (en) | External preparation for skin | |
JP2587751B2 (en) | Bath composition | |
JP2002332237A (en) | Skin care preparation | |
CA2801623A1 (en) | Agent for the treatment of skin conditions | |
JP2022102348A (en) | Oil-in-water topical skin preparation | |
JPH09249572A (en) | Antipruritic liquid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |